#NewAseBioMember | “AseBio and ICON together, is a collaborative network for the biotechnology field in Spain”

AseBio. What does your company's work bring to the table and what is its strength?

Pedro Vinals. ICON is the world's leading clinical research organisation powered by healthcare intelligence. We are a global provider of outsourced drug & device development and commercialisation services to pharmaceutical, biotechnology, medical device, government and public health organisations.

We specialise in the strategic development, management and analysis of programs that support Clinical Development from compound selection to Phase I – IV clinical studies.

AseBio. What is AseBio for you?

Pedro Vinals. AseBio and ICON together, is a collaborative network for the biotechnology field in Spain.

AseBio. When did you first hear about AseBio?

Pedro Vinals. AseBio was initially proposed by the local Business Development team in Spain.

AseBio. What do you expect from being part of an association like AseBio?

Pedro Vinals. ICON being part of AseBio will allow an expansion of our footprint in Spain and local visibility. We want to develop relations with key local leaders who believe in our vision.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Pedro Vinals. The struggle to access funding is threatening to significantly impact biotech drug development. Almost half (47%) of the respondents in a recent sector survey conducted by ICON, said the rising cost of capital will have the greatest influence on future operations, and 35% of people named cost management as the most significant barrier to innovation.